New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
09:19 EDTQCOR, MNK, CIReimbursement for Questcor Acthar by Cigna mostly unchanged, says CRT Capital
After Cigna (CI) updated its coverage policy for Questcor's (QCOR) Acthar, CRT Capital thinks the new rules may be viewed as more restrictive than previously. However, the firm thinks that Cigna's reimbursement policies for Actharfor indications other than MS flares are mostly unchanged. It keeps a Fair Value rating on Mallinkrodt, which has agreed to buy Questcor.
News For MNK;QCOR;CI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
June 19, 2015
16:24 EDTCIStocks end week higher after Fed reassures on gradual pace of rate increases
Subscribe for More Information
14:07 EDTCIOptions with increasing implied volatility: NFLX CI TRIP AET
10:09 EDTCIFly Watch: Supreme Court may release key ACA decision soon
Subscribe for More Information
09:18 EDTCIHumana most likely target in Managed Care, says FBR Capital
FBR Capital says Humana (HUM) is the most likely acquisition target in the Managed Care space, with Aetna (AET), Anthem (ANTM) and Cigna (CI) as the likely acquirers. The firm believes Anthem would benefit the most from the acquisition of Humana. It also thinks UnitedHealth (UNH) could look to acquire Aetna or Cigna. FBR thinks one or two more large deals in the space are possible.
07:37 EDTCISupreme Court decision on ACA suit due soon, says UBS
Subscribe for More Information
06:11 EDTCICigna implied volatility of 38 at upper end of index
Subscribe for More Information
June 18, 2015
11:31 EDTCIOptions with increasing implied volatility
Subscribe for More Information
07:51 EDTCIIncrease in 3R backstop most positive for Humana, says Leerink
Subscribe for More Information
06:57 EDTMNKMallinckrodt says Questcor facing multi-state antitrust probe
Subscribe for More Information
06:08 EDTCICigna implied volatility of 38 at upper end of index
June 17, 2015
11:08 EDTCIOptions with increasing implied volatility
Subscribe for More Information
07:48 EDTCIHealth insurers seen consolidating from five to three in 'megadeals,' WSJ says
Subscribe for More Information
07:42 EDTCIAetna price target raised to $145 from $135 at Leerink
Subscribe for More Information
07:21 EDTMNKGeneric ADHD drugs still sold despite FDA non-equivalance finding, NYT reports
The FDA announced last November that two generic versions of Johnson & Johnson's (JNJ) Concerta ADHD drug, one made by Mallinckrodt (MNK) and the other by UCB, could no longer be considered the equivalent of the branded drug after tests and analyses suggested that their effectiveness began to wear off much more quickly, but the drugs are still being sold despite an FDA mandated deadline having passed for the companies to either prove the drugs were equivalent or remove them from the market, said The New York Times. The report noted a third generic product, sold by Actavis (AGN), was found to be equivalent to the branded Concerta. Reference Link
07:16 EDTCICigna added to Most Preferred List, target raised to $175 at UBS
UBS added Cigna to its Most Preferred List and said the shares are attractive from both an operating and a consolidation perspective. The firm believes the risk/reward is attractive at current levels and applied a 30% probability of a buyout. UBS reiterated its Buy rating and raised its price target to $175 from $149 on Cigna shares.
June 16, 2015
12:58 EDTCIVolatility spiked for providers of health insurance following takeover reports
Subscribe for More Information
11:08 EDTCIUnitedHealth has information advantage over peers, says Piper Jaffray
Piper Jaffray analyst Sean Wieland writes that regardless of potential consolidation in the industry, UnitedHealth (UNH), following its acquisition of Optum, has an information advantage that could be years ahead of the other payors. Wieland says UnitedHealth's reported offer to acquire Aetna (AET) for $40B looks understated compared to Anthem's (ANTM) rejected $45B bid for Cigna (CI). He reiterates an Overweight rating on UnitedHealth with a $149 price target.
10:29 EDTMNKGeneric drugs may be targets of congressional price probe, Bloomberg says
In addition to branded drugs that were cited for "staggering" price increases in a congressional probe on drug prices being led by U.S. Senator Bernie Saunders, generic drug makers may also be targeted, stated Bloomberg Intelligence. Data show some generics, including clomipramine hydrochloride and tetracycline, have seen "aggressive" quarterly price increases, the report noted. Generic drug makers that could be caught up in the probe include Mallinckrodt (MNK), Teva (TEVA), Novartis' (NVS) Sandoz unit, Mylan (MYL), Taro Pharmaceutical (TARO) and Teva (TEVA). Mallinckrodt shares are down about 4% in early trading.
06:45 EDTCICigna price target raised to $180 from $145 at Deutsche Bank
Subscribe for More Information
05:53 EDTCIAetna approached by UnitedHealth about merger, WSJ reports
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use